rs11061937 — ADIPOR2 ADIPOR2 rs11061937

ADIPOR2 rs11061937: Hepatic Adiponectin Signaling and Cardiometabolic Risk

Adiponectin is one of the most abundant hormones secreted by fat tissue, and unlike most adipokines its levels paradoxically fall as body fat increases. Low circulating adiponectin is strongly associated with insulin resistance, type 2 diabetes, and cardiovascular disease¹¹ Low circulating adiponectin is strongly associated with insulin resistance, type 2 diabetes, and cardiovascular disease
Adiponectin acts as a key anti-inflammatory, insulin-sensitizing signal; its decline in obesity is a central mechanism linking excess body fat to metabolic dysfunction. The metabolic effects of adiponectin are transmitted through two receptors: ADIPOR1, dominant in skeletal muscle, and ADIPOR2, dominant in the liver. rs11061937 is an intronic variant in the ADIPOR2 gene — it does not change the receptor's amino acid sequence but may influence receptor expression levels or splicing, thereby modulating how efficiently the liver responds to adiponectin's metabolic instructions.

The Mechanism

ADIPOR2 in the liver activates two interconnected metabolic pathways downstream of adiponectin binding: the AMPK pathway²² AMPK pathway
AMP-activated protein kinase — a master metabolic sensor that switches cells from anabolic to catabolic mode, increasing fatty acid oxidation and glucose uptake while suppressing fat synthesis and the PPARα pathway³³ PPARα pathway
Peroxisome proliferator-activated receptor alpha — a nuclear receptor that governs transcription of genes for hepatic fatty acid oxidation and lipid export; ADIPOR2 is the primary activator of PPARα in liver. Together these pathways reduce hepatic fat accumulation, improve insulin sensitivity, and regulate LDL clearance and cholesterol synthesis. When ADIPOR2 expression is reduced — as occurs in obesity — PPARα activity in the liver falls, LDL clearance declines, and cholesterol synthesis rises⁴⁴ When ADIPOR2 expression is reduced — as occurs in obesity — PPARα activity in the liver falls, LDL clearance declines, and cholesterol synthesis rises
Demonstrated in a glucocorticoid stress model showing that decreased hepatic AdipoR2 impairs AMPK–PPARα signaling with measurable effects on LDL and cholesterol. The C allele at rs11061937 may tag a haplotype with altered ADIPOR2 expression or receptor function, making the liver less responsive to adiponectin's protective metabolic signals.

The Evidence

The most direct evidence for rs11061937 comes from the Finnish Diabetes Prevention Study (DPS)⁵⁵ Finnish Diabetes Prevention Study (DPS)
A landmark randomized lifestyle intervention trial in Finland enrolling people with impaired glucose tolerance (IGT); the DPS genotyping sub-study examined 484 participants for ADIPOR2 variants and cardiovascular outcomes. Eight ADIPOR2 SNPs were analyzed; four showed nominal association with CVD outcomes, and when these were entered into a joint multi-SNP model, rs11061937 remained independently significant (p = 0.014). This indicates the variant contributes unique CVD risk information above and beyond what other ADIPOR2 variants capture.

In contrast, a smaller study of 200 admixed Latin Americans found no association between rs11061937 and diabetes or hypertriglyceridemia⁶⁶ no association between rs11061937 and diabetes or hypertriglyceridemia
Mora-García et al. Variations in ADIPOR1 But Not ADIPOR2 are Associated With Hypertriglyceridemia and Diabetes in an Admixed Latin American Population. Review of Diabetic Studies, 2017, while ADIPOR1 variants in the same cohort showed significant associations (OR 3.88–4.72). This population and sample size difference may reflect genuine ancestry-specific effects or limited statistical power — the C allele frequency is notably higher in East Asian and Latino populations (~50% and ~48% respectively) than in Europeans (~32%), which changes the statistical architecture of association studies considerably.

More broadly, the gene's biology is well-established: synthetic ADIPOR agonists that activate both ADIPOR1 and ADIPOR2 reduce insulin resistance and extend lifespan in obese diabetic mice⁷⁷ reduce insulin resistance and extend lifespan in obese diabetic mice
Okada-Iwabu et al. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature, 2013, confirming the receptor system as a tractable target for metabolic disease. ADIPOR2 in particular is selectively downregulated in visceral obesity while ADIPOR1 expression is maintained⁸⁸ while ADIPOR1 expression is maintained
Demonstrated in adipose tissue and liver from obese subjects; ADIPOR2 uniquely responds to the obese microenvironment with progressive downregulation, suggesting it is a key point of metabolic vulnerability.

Practical Actions

The actionable levers for ADIPOR2-related signaling are strategies that raise circulating adiponectin and maintain hepatic receptor responsiveness. Adiponectin levels respond measurably to dietary composition: reducing saturated fat intake and increasing omega-3 fatty acid consumption raise adiponectin. Regular fasting glucose and lipid panel monitoring catches early metabolic drift, since ADIPOR2 signaling deficits manifest first as rising fasting glucose and triglycerides rather than overt diabetes. Given the Finnish DPS finding linking this variant to CVD outcomes — independent of T2D progression — cardiovascular risk markers (fasting lipids, hsCRP, blood pressure) are relevant monitoring targets.

Interactions

rs11061937 was analyzed alongside rs1058322, rs10848554, and rs16928751 in the Finnish DPS; these four SNPs were co-associated with CVD risk, suggesting they tag an extended ADIPOR2 haplotype with compounded effects on receptor function. Carrying C alleles at multiple ADIPOR2 loci likely amplifies the reduction in hepatic adiponectin responsiveness. For individuals who also carry lipid metabolism risk variants (e.g., in APOE, LDLR, or the triglyceride-fatty acid pathway), the combination of impaired ADIPOR2 signaling with intrinsically dysregulated lipid handling may represent a more significant cardiometabolic risk profile than either pathway alone.